Obesity pillars · 2026
Bitter hop nutraceutical stimulates fat mass loss while preserving muscle mass in a cohort of individuals with overweight or obesity receiving diet and exercise advice.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Walker Edward, Lo Kim, Smirk Isabel, Spence Marry Rose, Dinnan Hannah, Martell Sheridan, Lomiwes Dominic
Аннотация
BACKGROUND: Diet and exercise advice are routinely the primary interventions given for weight loss; however, frequently result in poor weight loss outcomes. While modern pharmaceuticals are highly effective, there exists a need for a non-pharmaceutical adjunct therapy for lifestyle change-mediated weight loss. Recently, the gastrointestinal delivery of a bitter hop-based nutraceutical has been shown to stimulate increases in glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK). Our aim was to determine if this same bitter hop nutraceutical is an effective adjunct therapy during prescribed weight loss programs.
METHODS: This was a randomized, double-blind, parallel treatment study. One hundred and fifty adult males and females were recruited and required to undertake a 24-week weight loss program consisting of monthly lifestyle advice group seminars. Daily treatments of either placebo or 500 mg of a bitter hop extract (BHE) were given to the participants, who were instructed to take half the daily dose at least 1 h before the two major meals of the day. Body weight, bioelectrical impedance analysis (BIA) of body composition, and subjective appetite and craving measures were taken every four weeks.
RESULTS: One hundred and twenty-eight participants completed the program. The BHE treatment group exhibited a greater reduction in weight (3.8%) and fat mass (3.9 kg) after 24 weeks when compared to placebo control (p < 0.05), and a total reduction of 4.3% body weight and 4.5 kg fat mass when compared to baseline values (p < 0.05). There was a proportionally similar reduction in BIA-estimated visceral fat area in the BHE treatment group relative to the placebo control (p < 0.05), and neither group exhibited any loss in BIA-estimated skeletal muscle mass.
CONCLUSION: These data suggest that appetite suppressing nutraceuticals may be a useful adjunct therapy for individuals receiving lifestyle change advice for the purpose of weight loss. Australia and New Zealand Clinical Trial Registry (ANZCTR- ACTRN12625001011471).
METHODS: This was a randomized, double-blind, parallel treatment study. One hundred and fifty adult males and females were recruited and required to undertake a 24-week weight loss program consisting of monthly lifestyle advice group seminars. Daily treatments of either placebo or 500 mg of a bitter hop extract (BHE) were given to the participants, who were instructed to take half the daily dose at least 1 h before the two major meals of the day. Body weight, bioelectrical impedance analysis (BIA) of body composition, and subjective appetite and craving measures were taken every four weeks.
RESULTS: One hundred and twenty-eight participants completed the program. The BHE treatment group exhibited a greater reduction in weight (3.8%) and fat mass (3.9 kg) after 24 weeks when compared to placebo control (p < 0.05), and a total reduction of 4.3% body weight and 4.5 kg fat mass when compared to baseline values (p < 0.05). There was a proportionally similar reduction in BIA-estimated visceral fat area in the BHE treatment group relative to the placebo control (p < 0.05), and neither group exhibited any loss in BIA-estimated skeletal muscle mass.
CONCLUSION: These data suggest that appetite suppressing nutraceuticals may be a useful adjunct therapy for individuals receiving lifestyle change advice for the purpose of weight loss. Australia and New Zealand Clinical Trial Registry (ANZCTR- ACTRN12625001011471).